Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. by Haferlach, T et al.
UCLA
UCLA Previously Published Works
Title
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
Permalink
https://escholarship.org/uc/item/07p8r0c1
Journal
Leukemia, 28(2)
ISSN
0887-6924
Authors
Haferlach, T
Nagata, Y
Grossmann, V
et al.
Publication Date
2014-02-01
DOI
10.1038/leu.2013.336
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
OPEN
LEADING ARTICLE
Landscape of genetic lesions in 944 patients with myelodysplastic
syndromes
T Haferlach1,10, Y Nagata2,4,10, V Grossmann1,10, Y Okuno2,10, U Bacher1, G Nagae3, S Schnittger1, M Sanada2,4, A Kon2,4, T Alpermann1,
K Yoshida2,4, A Roller1, N Nadarajah1, Y Shiraishi6, Y Shiozawa2,4, K Chiba6, H Tanaka5, HP Koeffler7,8, H-U Klein9, M Dugas9, H Aburatani3,
A Kohlmann1, S Miyano5,6, C Haferlach1, W Kern1,10 and S Ogawa2,4,10
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic
syndromes (MDS). We determined the biological and prognostic significance of genetic aberrations in MDS. In total, 944 patients
with various MDS subtypes were screened for known/putative mutations/deletions in 104 genes using targeted deep sequencing
and array-based genomic hybridization. In total, 845/944 patients (89.5%) harbored at least one mutation (median, 3 per patient;
range, 0–12). Forty-seven genes were significantly mutated with TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1 mutated in410%
of cases. Many mutations were associated with higher risk groups and/or blast elevation. Survival was investigated in 875 patients.
By univariate analysis, 25/48 genes (resulting from 47 genes tested significantly plus PRPF8) affected survival (Po0.05). The status of
14 genes combined with conventional factors revealed a novel prognostic model (‘Model-1’) separating patients into four risk
groups (‘low’, ‘intermediate’, ‘high’, ‘very high risk’) with 3-year survival of 95.2, 69.3, 32.8, and 5.3% (Po0.001). Subsequently,
a ‘gene-only model’ (‘Model-2’) was constructed based on 14 genes also yielding four significant risk groups (Po0.001). Both
models were reproducible in the validation cohort (n¼ 175 patients; Po0.001 each). Thus, large-scale genetic and molecular
profiling of multiple target genes is invaluable for subclassification and prognostication in MDS patients.
Leukemia (2014) 28, 241–247; doi:10.1038/leu.2013.336
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INTRODUCTION
Myelodysplastic syndromes (MDS) are a heterogeneous group of
myeloid neoplasms characterized by varying degrees of
cytopenias and a predisposition to acute myeloid leukemia.1
With conspicuous clinical and biological heterogeneity in MDS,
an optimized choice of treatment based on accurate diagnosis
and risk stratification in individual patients is central to the
current therapeutic strategy.2 In fact, relying on conventional
cytogenetics, cytomorphology and peripheral blood parameters,
the International Prognostic Scoring System (IPSS) and other
models2–4 have been successfully used for these purposes, and the
recent revision of IPSS (IPSS-R) further improved prognostication.5
Meanwhile, our knowledge about the molecular pathogenesis
of MDS has dramatically improved during the past 10 years
mainly through the identification of major mutational targets.6
These mutations not only involved previously well-defined
pathways such as signal-transducing molecules and transcription
factors, but also affected newly identified pathways, including
epigenetic regulators such as TET2,7 IDH1/2,8,9 DNMT3A,10 ASXL111
and EZH2,12,13 and multiple components of the RNA-splicing
machinery,14–16 and the list of gene mutations implicated in MDS
pathogenesis17,18 is still growing. A recent study described
oncogenic mutations in 78% of patients with MDS or closely
related myeloid neoplasms.19 Further studies are warranted to
clarify how to integrate this increased knowledge of gene
mutations in our understanding of MDS pathogenesis and into
clinical practice, which is even more emphasized by the recent
advance of high-throughput genomics. Bejar et al.20,21 recently
suggested that the mutational status of multiple gene targets
could better predict the clinical outcome in MDS. According to
ELN (European Leukemia Network) recommendations, mutation
analysis of candidate genes that can allow a conclusive diagnosis
and a reliable prognostic evaluation is already suggested in
patients with MDS.22
The purpose of the present study was to provide a solid basis
for applying the knowledge of this group of gene mutations to
medical practice and to further understanding of MDS pathoge-
nesis, using revolutionized technologies for genome analysis.23,24
We investigated a large cohort of 944 patients with different MDS
subtypes for genetic lesions, in which gene mutations and copy
number alterations in a total of 104 known/putative gene targets
were comprehensively analyzed using massively parallel sequencing.
This set of information about genetic lesions was utilized to
build novel prognostic models that outperformed existing models,
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employing a conventional training/validation-cohort design.
Analyses of spectrum of mutations and their mutational
burdens and correlation of different mutations also provided
novel insights into intratumoral heterogeneity and hierarchy of
mutations, together with their association to phenotypes.
PATIENTS AND METHODS
Patients
A total of 944 adult patients with different MDS subtypes were enrolled in
this study, whose bone marrow and peripheral blood samples had been
sent for diagnosis to the MLL Munich Leukemia Laboratory between
August 2005 and August 2011 (Table 1). The training cohort consisted of
730 patients, the validation cohort of 214 patients. In the training cohort
(n¼ 730 patients), follow-up data was available in 670 cases, information
on treatment in 648 cases (supportive care: n¼ 504/648, 77.8%;
azacytidine or lenalidomide: n¼ 62/648, 9.6%; cytoreductive treatment
only: 22/648, 3.4%; acute myeloid leukemia-induction therapy: n¼ 60/648,
9.3%). In the independent validation cohort (n¼ 214 patients), data on
follow-up was available in 205, on therapy in 192 patients with a similar
distribution of therapeutic strategies (supportive care: n¼ 148/192, 77.1%;
azacytidine or lenalidomide: n¼ 18/192, 9.4%; cytoreductive treatment:
n¼ 11/192, 5.7%; acute myeloid leukemia-induction therapy: n¼ 15/192;
7.8%). Non-amplified genomic DNA from 53 healthy individuals and paired
tumor/normal DNA from an additional 16 MDS cases were also analyzed
and used for performance of our data analysis pipelines. All samples were
investigated by cytomorphology, chromosome banding analysis, and in
part, fluorescence in situ hybridization (Supplementary Table S1), and
standard molecular analyses. All patients gave their written informed
consent with genetic analyses and with research studies. The study was
approved by the internal review boards of the MLL and the University of
Tokyo and was following the Declaration of Helsinki.
Procedures
In total, 104 known or putative mutational gene targets in MDS were
examined for mutations in all 944 cases from the cohort using massively
parallel sequencing (Illumina, San Diego, CA, USA) of SureSelect (Agilent,
Santa Clara, CA, USA) captured target sequences (Supplementary Tables S2
and S3 and Methods in the Supplementary Information). All sequencing data
were analyzed using our in-house pipeline, through which high-probability
oncogenic mutations were called by eliminating sequencing/mapping errors
and known/possible SNPs based on the available databases and frequencies
of variant reads (Supplementary Figures S1 and S2 and Methods in the
Supplementary Information). Genomic copy number status was calculated by
directly enumerating corresponding sequencing reads in each exon, and also
assessed by array-based comparative genomic hybridization (aCGH) in 494
(76.2%) out of 648 samples with normal karyotypes. Genome-wide
methylation status was measured in 191 patients using Infinium 450K arrays
(Illumina) (Supplementary Information).
Impact of genetic lesions on overall survival (OS) was investigated by
Cox regression, in which the Least Absolute Shrinkage and Selection
Operator (lasso)25,26 was used for selecting variables. The linear predictor
from the Cox regression was then used to assign the patients into discrete
risk groups. Prognostic models were constructed in a training set and
confirmed using an independent validation cohort and their performance
was compared to the IPSS-R using the Akaike information criterion and
J-tests.27 Detailed information describing mutation/copy number calling,
cytomorphology, chromosome banding analysis, array comparative
genomic hybridization (aCGH), risk prediction model building, global
methylation studies and other statistical analyses are given in the
Supplementary Information.
RESULTS
Targeted sequencing
The mean depth of the targeted resequencing study in 104 genes
was 1066-fold (257–2306 reads) across the entire cohort (n¼ 944).
More than 99% of the target sequences (that is, 357 861 bp
nucleotides including six bases from a splice junction) were
analyzed with 430 independent reads. After excluding sequen-
cing/mapping errors and known or possible polymorphisms,
a total of 2764 single nucleotide variants and insertions/deletions
(indels) were called in 96 genes as high-probability somatic
changes (Figure 1a and Supplementary Figure S3). For validation,
we sequenced randomly selected 300 variants (Supplementary
Table S4) using independent sequencing platforms (Sanger
sequencing and/or Illumina MiSeq), of which 299 were success-
fully confirmed (99.7%). Our pipeline generated only 10 false-
positive calls, when applied to the analysis of DNA from 53 healthy
individuals (Supplementary Information). The accuracy of our
pipeline was also assessed by using paired tumor/normal DNA
from 16 MDS cases, in which 74 of 75 (98.7%) mutations called by
our pipeline were confirmed as being true somatic mutations
using normal DNA. Finally, further cross-validation was performed
for a total of 1207 gene loci among 446 MDS cases, in which an
overall concordance of 99.4% congruent results was observed
(Supplementary Information).
Frequency and spectrum of gene mutations
In total, 845 of the 944 patients (89.5%) harbored at least one
mutation with a median of 3 (0–12) mutations per sample,
Table 1. Demographic data, peripheral blood parameters, MDS
subtypes, results of cytogenetics and risk classification according to
IPSS/IPSS-R for the total cohort
Parameter Total cohort (n¼ 944)
Patient numbers
(ratios, ranges or percentages)
Demographic characteristics 944
Males:females (ratio) 580:364 (1.6)
Median age (years) 72.8 (23.3–90.8)
o50 46 (4.9%)
50–o60 81 (8.6%)
60–o70 240 (25.4%)
70–o80 423 (44.8%)
X80 154 (16.3%)
Cases with follow-up 875
Median follow-up in months 32.3
Median OS in months 54.5
MDS subtypes (WHO, 2008) 944
RA 41 (4.3%)
RARS 81 (8.6%)
RARS-T 28 (3.0%)
RCMD 195 (20.7%)
RCMD-RS33 183 (19.4%)
RAEB-1 191 (20.7%)
RAEB-2 188 (19.9%)
MDS with isolated 5q-deletion 37 (3.9%)
Cytogenetics 944
Normal karyotype 648 (68.6%)
Aberrant karyotype 296 (31.4%)
IPSS risk group 848
Low 324 (38.2%)
Intermediate-1 319 (37.6%)
Intermediate-2 171 (20.2%)
High 34 (4.0%)
IPSS-R risk group 848
Very low 122 (14.4%)
Low 340 (40.1%)
Intermediate 203 (23.9%)
High 130 (15.3%)
Very high 53 (6.3%)
Abbreviations: IPSS, International Prognostic Scoring System; MDS,
myelodysplastic syndrome; OS, overall survival.
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in which 574 (67.9%) cases had a normal karyotype (Supplementary
Figure S4). In 19 cases gene deletions without mutations were
observed. Sixty-eight genes were mutated in 40.5% of the cases
and 47 genes were considered as statistically significantly mutated
(qo0.01) after calculating type I errors for 104 genes following the
method of Benjamini and Hochberg28 (Supplementary Table S5
Figure 1. Significantly mutated genes in MDS. (a) Frequency of mutations in 47 significantly mutated genes in 944 cases with different WHO
subtypes, which are shown in indicated colors. (b) Frequency of gene mutations involved in common functional pathways, which are defined
in Supplementary Table S3. (c) Number of gene mutations detected in different MDS subtypes. (d) Distribution of mutations/deletions of
significantly mutated genes in 944 MDS cases.
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and Methods in the Supplementary Information). The six most
frequently mutated genes were TET2, SF3B1, ASXL1, SRSF2,
DNMT3A and RUNX1 (mutated in 410% of the cases). Less
common mutations (2–10%) involved U2AF1, ZRSR2, STAG2, TP53,
EZH2, CBL, JAK2, BCOR, IDH2, NRAS, MPL, NF1, ATM, IDH1, KRAS,
PHF6, BRCC3, ETV6 and LAMB4 (Figure 1a). Most of the significantly
mutated genes were previously well documented either in MDS or
other myeloid malignancies. However, some were newly identified
or re-confirmed as recurrently mutated genes, including BRCC3,14
FANCL, LUC7L2,29 STAG2 and other cohesin components17 such as
RAD21, SMC3 and SMC1A,30 or CTCF, GPRC5A, LAMB4 and IRF1.31,32
Mutated genes were grouped into several functional pathways,
which were hypothesized to characterize MDS pathogenesis
(Supplementary Figure S5). Amongst these, the most frequent
target was RNA splicing, with mutations observed in as many as
64% of cases, followed by genes associated with DNA methylation,
chromatin modification, transcription, RAS/signal transduction
pathways, cohesin and DNA repair pathways (Figure 1b). The
mean number and the spectrum of mutations closely correlated
with WHO subtypes. SF3B1 mutations were frequently confirmed
in MDS subtypes with increased ring sideroblasts (240/292,
82.2%) and also in isolated del(5q) (9/37, 24.3%). Except for
SF3B1, DNMT3A, JAK2 and MPL mutations, the majority of common
mutations occurred more frequently in high-risk WHO subtypes
(RAEB-1/-2), than in RA/RARS cases (Figure 1a). Similarly, the mean
number of mutations tended to be higher in high-risk subtypes
(Figure 1c). Notably, even in RA and RCMD with normal karyotype,
gene mutations were found in 133/183 cases (72.7%). Some tumor
suppressor genes were also identified as common targets of gene
deletions as revealed by conventional cytogenetics, aCGH, and/or
digital copy number analyses, which included EZH2, LUC7L2, ETV6,
TET2, IRF1, TP53 and PHF6 (Supplementary Figures S6 and S7).
Combined, these data provide a landscape of genetic alterations
in MDS (Figure 1d).
Correlation of gene mutations
Statistically significant correlations (qo0.01) were found across 82
combinations of significantly mutated genes, indicating the
presence of functional interactions among different mutations in
MDS pathogenesis. These included correlations, such as positive
correlations among mutations/deletions in STAG2, IDH2, ASXL1,
RUNX1 and BCOR, and mutually exclusive relationships between
SRSF2 mutations and mutations/deletions of DNMT3A, EZH2, IRF1
and between ASXL1 and DNMT3A (Figure 2a). Reflecting lower
number of coexisting mutations in SF3B1-mutated cases, SF3B1
mutations largely showed negative correlations with common
mutational targets other than DNMT3A and JAK2 mutations.
ASXL1 mutations were more likely to coexist with other mutations,
except for significantly negative correlations with SF3B1, DNMT3A
and IRF1 mutations. TET2 mutations showed positive correlations
with SRSF2 and ZRSR2 mutations.
Intratumoral heterogeneity and hierarchy of mutations
Accurate determination of variant allele frequencies (VAFs) by
deep sequencing allowed for investigating substructures within
the tumor population in terms of gene mutations, relying on a
modified w2 test for heterogeneity (Supplementary Figure S8 and
Methods in the Supplementary Information). Intratumoral hetero-
geneity was recognized in as many as 456 cases (48.3%), even
though the small number of gene mutations available for
evaluation was thought substantially to underestimate the real
frequency. The number of observed intratumoral subpopulations
tended to correlate with the number of detected mutations and
therefore, advanced WHO subtypes and risk groups with poorer
prognosis (Supplementary Figure S9).
Mean VAFs showed significant variations among major gene
targets (Supplementary Figure S10). Specifically, when VAFs of
Figure 2. Comparison of mutation loads between major gene
targets in MDS. (a) Correlations between major genetic lesions,
where the correlation coefficients are indicated by a color gradient
and show diagonal plots of variant allele frequencies (VAFs)
between ASXL1 and U2AF1 mutations (b) and between mutations
in RAS pathway genes (CBL, KRAS, NF1, NRAS and PTPN11) and DNA
methylation-related genes (TET2, IDH1/2 and DNMT3A) (c), in which
copy number-adjusted VAF values between indicated mutations or
mutations of indicated functional pathways were compared using
paired T-tests. Comparison was made exhaustively between all
possible combinations of commonly mutated genes (42.5% of
mutation rates) (d) or gene pathways (e) with adjustment for
multiple testing. Significance (q-values) and difference (relative
difference in VAFs) is indicated by the size of circles and color
gradient, as indicated, respectively.
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coexisting genes and/or pathway genes were compared between
major gene targets (N¼ 47) or target pathways (N¼ 9), significant
difference was demonstrated in 28 out of 224 gene pairs and 18
out of 36 pathway pairs investigated (Figures 2b–e, Supplementary
Table S6). These results suggested clonogenic hierarchy among
these common mutations during clonal evolution. For example,
mutations in genes on DNA methylation and RNA splicing
pathways tended to have higher mutation burden than those in
other genes, suggesting earlier origins of these mutations
(Figures 2c and d). Also, mutations of genes involved in chromatin
modifications and transcriptions tended to have higher VAFs than
RAS pathway mutations (Figure 2e). Similarly, RARS-T cases
were characterized by a coexisting JAK2 mutation, in which
all but one JAK2 mutations showed significantly lower mutation
burden than the corresponding SF3B1 mutation, strongly
suggesting that most RARS-T cases evolved from RARS/RCMD-RS
with an additional acquisition of a JAK2 mutation (Supplementary
Figure S11).
Development of a novel prognostic model including molecular
markers
The impact of these genetic lesions on clinical outcomes was
initially investigated in 875 patients, in which follow-up data were
available. In univariate analysis, 25 out of 48 genes (resulting from
47 genes tested significantly plus PRPF8) affected OS (Po0.05)
(Supplementary Figure S12), and only SF3B1 mutations were
associated with a better clinical outcome. Next, to evaluate the
combined effect of these multiple gene mutations/deletions,
together with common clinical/cytogenetic variables used for
IPSS-R, OS was modeled by a conventional Cox regression. For this
purpose, complete follow-up data and other clinical/cytogenetic
data were available in 786 patients, of which 611 were used as a
training set, while the remaining 175 were used for validation
(Supplementary Information). To reduce the initial set of putative
explanatory variables, we included only 32 genes in the regression
analysis that were altered in at least 15 patients of the training
set, and then performed variable selection using lasso (Methods in
the Supplementary Information).
A total of 14 genes, together with age, gender and, using the
categories of the IPSS-R, white blood cell counts, hemoglobin,
platelet counts, bone marrow blast count and cytogenetic score
were finally selected for the Cox regression in a proportional
hazard model (Figure 3a and Supplementary Tables S7 and S8).
Based on the linear predictor of the regression model, we
constructed a prognostic model (Model-1), in which patients were
classified into four risk groups showing significantly different OS
(‘low’, ‘intermediate’, ‘high’ and ‘very high risk’) with significantly
differing 3-year survival of 95.2, 69.3, 32.8 and 5.3%, respectively
(Po0.001; Figure 4a). The model was largely reproducible in the
validation cohort of 175 patients (Po0.001; Figure 4d) and also in
the 463 patients who were treated with supportive care only
(Po0.001; Supplementary Figure S13). When the variables for a
new lasso model were limited to genes only (results of Cox
regression in a proportional hazard model shown in Figure 3b), a
prognostic model (gene-only model; Model-2) was generated
based on 14 selected genes yielding four significant risk groups
(Po0.001; Figure 4b), which was also statistically reproduced in
the validation set (Po0.001; Figure 4e and Supplementary Table
S9). Significantly, 13 of the 14 genes selected for Model-1 were
again selected for Model-2.
These results demonstrated that the mutation/deletion status of
a set of genes could be used to build a clinically relevant
prognostic system as independent variables from clinical para-
meters. When applied to the validation cohort (Figures 4d–f),
Model-1 was shown to outperform the IPSS-R (Figure 4f; see also
Figure 4c for training cohort according to IPSS-R) and Model-2
(Figure 4e). The superiority of Model-1 was also indicated by the
J-test: adding the predictions from Model-1 to the IPSS-R
model significantly improved the model (Po0.001), whereas the
predictions from the IPSS-R did not substantially improve
Model-1. As expected, when comparing Model-2 to the IPSS-R,
the J-test indicates that both models could be improved by
information from the other model (Supplementary Table S10;
Figure 3. Illustration of hazard ratios for Model-1 and Model-2. Hazard ratios (HRs, given in numbers) as well as logHR and their 95%
confidential intervals (given as chart) for parameters used for Model-1 including clinical and genetic variables (a) and for Model-2 including
only genetic variables (referring to the training cohort) (b) are plotted. For a, baseline level for the analysis was the respective IPSS-R risk
category with the least risk score (hemoglobin: X10 g/dl, platelets score: X100 109/l, blast score: p2%, cytogenetic score very good).
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see also Supplementary Information and Supplementary Figure
S21A–E). The results did not change remarkably when the
validation cohort was reduced to only samples with supportive
treatment (see Supplementary Information).
We investigated possible correlations of the before mentioned
genes with WHO classification, risk categories in IPSS/IPSS-R and
Model-1/2, karyotypes, demographic and clinical data within the
training cohort (Supplementary Tables S11 and S12). ASXL1
(P¼ 0.021) and TET2 (P¼ 0.007) mutations were significantly
associated with male sex. Patients with TET2 mutations
(Po0.001) showed a higher mean age as compared with patients
without the respective mutations. Most of the above mutations
were associated with higher risk groups and/or with MDS
subtypes with elevated blast counts (Supplementary Figures
S14-S17).
DISCUSSION
High-throughput deep sequencing of the 104 gene targets across
944 MDS patients, combined with genome-wide copy number
analyses, revealed a large-scale comprehensive landscape of
genetic lesions in MDS with a broad spectrum of gene mutations
and deletions. Combined with copy number abnormalities,
genetic lesions were demonstrated in as many as 864/944
(91.5%) of MDS cases. This even exceeds the frequency of gene
mutations in another large-scale gene sequencing study in MDS
published recently.19 It should be emphasized that there was an
extremely high concordance rate between the results of NGS and
other molecular diagnostic techniques that were used for
secondary validation in part of the patients in our cohort. Given
the deep sequencing depths uniformly achieved over the entire
target sequences, we could expect highly sensitive detection of
mutations, except for false-negative detection of some indels,
especially those having large insertion/deletion size. This is also
true for other mutations that had very high (40.45) allelic burdens
and were previously unreported and for mutations existing in very
small subclones only (further details are given in Supplementary
Information). Also, the lack of germline controls and the technical
limitations in the current sequencing devices/chemistry may have
produced some false positives, even after extensive exclusion of
known SNPs and possible sequencing errors.
A paucity of known gene mutations was a characteristic feature
of RA and other low-risk MDS and correlated with better clinical
outcome, whereas higher numbers of gene mutations were
observed in advanced WHO subtypes. Heterogeneity of tumor
population in MDS17 has now been confirmed to be quite
common in MDS and more prominent in advanced WHO subtypes
and high-risk prognostic groups, which were also associated with
increasing numbers of gene mutations and intratumoral
subpopulations. Taken together, accumulating numbers of gene
mutations and increasing intratumoral heterogeneity characterize
the clonal evolution of MDS and are associated with a worse
prognosis. The presence of a hierarchy of mutations was another
important finding, which not only advances our understanding of
MDS pathogenesis, but also may suggest a clinical relevance in
molecular monitoring of disease progression. The gene mutations
found in our study were found to show significant correlations,
many of which were confirming recently published data,19
for example, the positive correlation of TET2 and ZRSR2 mutations,
or the negative correlation of ASXL1 and SF3B1 mutations.
However, probably the most significant finding of the current
study was the feasibility of testing mutations in multiple genes
(4100 candidates), based on which we can improve the way to
predict the prognosis of patients with MDS to enhance making
clinical decisions. In fact, correlation between multiple genetic
lesions and clinical outcome was so close to allow for building
novel, clinically applicable prognostic models for MDS. Thus,
further combining the 14 prognostic genes with conventional risk
factors, such as age, gender and the parameters used in the IPSS-R,
our model successfully discriminated four significant risk groups
and better predicted patients’ OS than gene-only model (Model-2)
and IPSS-R. This combined model succeeded to discriminate four
risk groups (‘low’, ‘intermediate’, ‘high’ and ‘very high risk’) with
significantly differing 3-year survival 95.2, 69.3, 32.8 and 5.3%
(Po0.001), respectively. It should be pointed out that 477% of
patients from both the training and the validation cohort in our
study had received supportive treatment only, but part of the
patients had received therapy, for example, with demethylating
agents. However, we were able to confirm the prognostic power
Figure 4. Development of a novel prognostic risk classification.
(a) Kaplan–Meier estimates of OS in months (m) for four groups
according to Model-1 in the training cohort. Three-year OS for low,
intermediate, high and very high-risk groups amounts to 95.2, 69.3,
32.8 and 5.3%, respectively. (b) Kaplan–Meier estimates of OS for
four groups according to Model-2 in the training cohort. Three-year
OS for low, intermediate, high and very high-risk groups amounts to
83.3, 66.4, 39.7 and 9.5%, respectively. (c) Kaplan–Meier estimates of
OS for five groups according to IPSS-R in the training cohort.
Three-year OS for very low, low, intermediate, high and very
high-risk groups amounts to 88.2, 73.9, 51.9, 45.3 and 19.6%,
respectively. (d) Kaplan–Meier estimates of OS for four groups
according to Model-1 in the validation cohort. Three-year OS for low,
intermediate, high and very high-risk groups amounts to 88.3, 84.4,
55.7 and 22.8%, respectively. (e) Kaplan–Meier estimates of OS for
four groups according to Model-2 in the validation cohort. Three-
year OS for low, intermediate, high and very high-risk groups
amounts to 83.3, 77.0, 64.1 and 33.3%, respectively. (f ) Kaplan–Meier
estimates of OS for five groups according to IPSS-R in the validation
cohort. Three-year OS was 83.3, 93.7, 59.3 and 57.1% for the very
low, low, intermediate and high-risk groups. For the very high-risk
group, the median OS was 9.2 months, as 3-year OS was not
applicable.
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of our prognostic Model-1 separately in part of the patients from
the training cohort who received supportive treatment only.
In conclusion, comprehensive molecular genetic profiling using
deep-sequencing is a feasible19 and highly promising approach
to contribute to diagnostic accuracy, pathogenesis, biologic
subclassification and finally prognostication and risk stratification
in patients with MDS. Considering the decrease of costs for this
technology and therefore its availability for large numbers of
patients in the near future, molecular profiling of multiple target
genes is feasible and soon will be integrated in individualized
therapeutic decision making for patients with MDS.
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